Dexamethasone in Controlling Dyspnea in Patients With Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03367156 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 8, 2017
Results First Posted : December 21, 2022
Last Update Posted : December 21, 2022
|
Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase II trial studies how well dexamethasone works in controlling dyspnea in patients with cancer. Dexamethasone may help control dyspnea (shortness of breath) and improve lung function and quality of life in cancer patients.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Dyspnea Malignant Neoplasm | Drug: Dexamethasone Other: Placebo Other: Questionnaire Administration | Phase 2 |
PRIMARY OBJECTIVES:
I. Compare the intensity of dyspnea (numeric rating scale [NRS]) in the dexamethasone arm with that in the placebo arm at week 1.
SECONDARY OBJECTIVES:
I. Compare the effects of dexamethasone with those of placebo in terms of personalized dyspnea response (based on a personalized dyspnea goal), unpleasantness of dyspnea, other symptoms, health-related quality of life, respiratory physiologic function, and adverse effects at week 1 and week 2, as well as the intensity of dyspnea at week 2.
II. Identify predictive markers of dyspnea response to dexamethasone.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive dexamethasone orally (PO) twice daily (BID) on days 1-28 in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at days 28 and 42.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 135 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Supportive Care |
| Official Title: | A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients |
| Actual Study Start Date : | December 4, 2017 |
| Actual Primary Completion Date : | May 5, 2021 |
| Estimated Study Completion Date : | December 31, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Breathing Problems
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group I (dexamethasone)
Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
|
Drug: Dexamethasone
Given PO
Other Names:
Other: Questionnaire Administration Ancillary studies |
|
Active Comparator: Group II (placebo, dexamethasone)
Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
|
Drug: Dexamethasone
Given PO
Other Names:
Other: Placebo Given PO
Other Names:
Other: Questionnaire Administration Ancillary studies |
Primary Outcome Measures :
- Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 7 Average Intensity [ Time Frame: Baseline and Day 7 ]The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea scores between Baseline and Day 7 were measured. Linear model analysis was used for analysis.
Secondary Outcome Measures :
- Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 14 Average Intensity [ Time Frame: Baseline and Day 14 ]The average dyspnea intensity over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea scores between Baseline and Day 14 were measured. Linear model analysis was used for analysis.
- Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 7 Average Unpleasantness [ Time Frame: Baseline and Day 7 ]The average dyspnea unpleasantness over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea unpleasantness scores between Baseline and Day 7 were measured. Linear model analysis was used for analysis.
- Change in Edmonton Symptom Assessment Scale (ESAS) Dyspnea Score Between Baseline and Day 7 [ Time Frame: Baseline and Day 7 ]ESAS (Edmonton Symptom Assessment Scale) is a validated scale ranging from 0 (not at all) to 10 (very much) used to assess 10 symptoms commonly experienced by cancer patients during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep and feeling of well being. The change in ESAS fatigue score between Baseline and Day 7 were measured. Total ESAS fatigue score ranged from 0-10, with a higher score indicating higher fatigue. Linear model analysis was used for analysis.
- Change in European Organization for Research and Treatment of Cancer-Quality of Life (EORTC QLQ-C30) Dyspnea Score Between Baseline and Day 7 [ Time Frame: Baseline and Day 7 ]European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated quality-of-life assessment for patients with cancer, consisting of 30 questions that encompass three symptom scales (pain, fatigue, and nausea/vomiting) and six questions about single symptoms, as well as five functional scales (physical, cognitive, role, emotional, and social) and one scale assessing global health status/quality of life. Each single symptoms have four response categories (1=not at all, and 4=very much). The change in EORTC fatigue score between Baseline and Day 7 were measured. Total scores using a complex scoring procedures ranges from 0 to 100 with a higher scores indicating higher fatigue. Linear model analysis was used for analysis.
- Change in Dyspnea Numeric Score Over the Past 24 Hours for Baseline and Day 14 Average Unpleasantness [ Time Frame: Baseline and Day 14 ]The average dyspnea unpleasantness over the past 24 hours was assessed daily using a validated numeric rating scale from 0 to 10. The total score ranged from 0-10 where higher scores indicate worse dyspnea. The change in Dyspnea unpleasantness scores between Baseline and Day 14 were measured. Linear model analysis was used for analysis.
- Change in Edmonton Symptom Assessment Scale (ESAS) Dyspnea Score Between Baseline and Day 14 [ Time Frame: Baseline and Day 14 ]ESAS (Edmonton Symptom Assessment Scale) is a validated scale ranging from 0 (not at all) to 10 (very much) used to assess 10 symptoms commonly experienced by cancer patients during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep and feeling of well being. The change in ESAS fatigue score between Baseline and Day 14 were measured. Total ESAS fatigue score ranged from 0-10, with a higher score indicating higher fatigue. Linear model analysis was used for analysis.
- Change in European Organization for Research and Treatment of Cancer Quality of Life (EORTC) Dyspnea Score Between Baseline and Day 14 [ Time Frame: Baseline and Day 14 ]European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated quality-of-life assessment for patients with cancer, consisting of 30 questions that encompass three symptom scales (pain, fatigue, and nausea/vomiting) and six questions about single symptoms, as well as five functional scales (physical, cognitive, role, emotional, and social) and one scale assessing global health status/quality of life. Each single symptoms have four response categories (1=not at all, and 4=very much). The change in EORTC fatigue score between Baseline and Day 14 were measured. Total scores using a complex scoring procedures ranges from 0 to 100 with a higher scores indicating higher fatigue. Linear model analysis was used for analysis.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of cancer.
- Dyspnea with an average intensity >= 4 on the dyspnea NRS (range 0-10) over the past week.
- Radiologic suspicion of thoracic involvement, such as primary or metastatic lung cancer, lymphangitic carcinomatosis, airway infiltration, lymphadenopathy, pleural or chest wall invasion.
- Seen at an outpatient clinic at MD Anderson Cancer Center or Lyndon B. Johnson (LBJ) Hospital General Oncology Clinic.
- Able to communicate in English or Spanish.
- Karnofsky performance status >= 30%.
Exclusion Criteria:
- Delirium (i.e., score > 13 on the Memorial Delirium Assessment Scale; range 1-30).
- Oxygen saturation < 90% despite supplemental oxygen > 6 L/minute.
- Previous allergic reactions to dexamethasone.
- Diagnosis of diabetes mellitus uncontrolled with oral hypoglycemic agents or insulin.
- Postsurgical open wound that has not healed at the time of enrollment.
- Any infection requiring antibiotics at the time of study enrollment.
- Major surgery within the past 2 weeks.
- Megestrol use at the time of study enrollment.
- Neutropenia (absolute neutrophil count < 1.0 x 10^9/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).
- Currently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist.
- Severe anemia (hemoglobin < 8 g/L) not corrected prior to study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).
- Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment.
- Heart failure exacerbation at the time of study enrollment.
- Expected to undergo therapeutic thoracentesis in the next 2 weeks.
- High anxiety score (>= 15/21) on the Hospital Anxiety and Depression Scale (HADS).
- Chronic systemic corticosteroid use (> 14 days) at the time of study enrollment.
- Any expected corticosteroid use during study enrollment at higher doses than will be used in this study.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03367156
Locations
| United States, Texas | |
| Lyndon B. Johnson Hospital | |
| Houston, Texas, United States, 77026 | |
| Harris Health System Settegast Health Center | |
| Houston, Texas, United States, 77028 | |
| M D Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | David Hui | M.D. Anderson Cancer Center |
Study Documents (Full-Text)
Documents provided by M.D. Anderson Cancer Center:
Documents provided by M.D. Anderson Cancer Center:
Study Protocol and Statistical Analysis Plan [PDF] March 7, 2022
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT03367156 |
| Other Study ID Numbers: |
2017-0591 NCI-2018-01129 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2017-0591 ( Other Identifier: M D Anderson Cancer Center ) |
| First Posted: | December 8, 2017 Key Record Dates |
| Results First Posted: | December 21, 2022 |
| Last Update Posted: | December 21, 2022 |
| Last Verified: | November 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Neoplasms Dyspnea Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Dexamethasone Dexamethasone acetate Ichthammol BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Dermatologic Agents |